Mast cell leukemia medical therapy
|
Mast cell leukemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mast cell leukemia medical therapy On the Web |
|
American Roentgen Ray Society Images of Mast cell leukemia medical therapy |
|
Risk calculators and risk factors for Mast cell leukemia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]
Overview
The mainstay of therapy for symptomatic mast cell leukemia patients is immunochemotherapy.[1]
Medical Therapy
Therapeutic approaches are limited and consist of reducing the tumor burden and conservation of organ functions.
Corticosteroids
- Corticosteroids have been recommended as a short term use in combination with cytotoxic drugs.[1]
- It could also be beneficial in some situations such as:
- Malabsorption
- Ascites
- Anaphylaxis
Interferon-α
Interferon-α reduces the frequency of:[1]
- Histamine related attacks
- Decrease bone marrow infiltration by mast cells
- Decrease liver infiltration by mast cells
- Decrease skin manifestations
- Improve osteoporosis
2-Chloro-deoxy-adenosine
2-Chloro-deoxy-adenosine has a potential value in the treatment of mast cell leukemia with symptomatic responses and improvement in mast cell variables.[1]
Cladribine
Cladribine has been used in rare cases of mast cell leukemia with relatively small or no efficacy.[1]
Imatinib
Imatinib does not have direct effect on the D816V KIT mutation, but it may affect other sporadic mutations.[1]
Dasatinib
Dasatinib demonstrates significant inhibitory activity against WT KIT as well as juxtamembrane domain mutant KIT. This activity has been proven in patients negative for D816V KIT.[1]
Nilotinib Masatinib Midostaurin
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Joris, Magalie; Georgin-Lavialle, Sophie; Chandesris, Marie-Olivia; Lhermitte, Ludovic; Claisse, Jean-François; Canioni, Danielle; Hanssens, Katia; Damaj, Gandhi; Hermine, Olivier; Hamidou, Mohammed (2012). "Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive". Case Reports in Hematology. 2012: 1–6. doi:10.1155/2012/517546. ISSN 2090-6560.